Cencora stock: Wells Fargo lifts target to 400 dollars
Published on 11/21/2026 at 10:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWeekly broker view and deal risk
- Wells Fargo retained its Overweight rating while updating its Cencora model for the company's new segmentation.
- The Federal Trade Commission's lawsuit over the planned MWI Animal Health sale remains a material transaction issue for investors.
- Cencora's latest Lang & Schwarz quote provides the trading context for the week ahead.
Wells Fargo raised its price target for Cencora on Tuesday, November 17, while keeping an Overweight rating on the shares. Investing.com, citing Reuters, reported that the bank updated its model to reflect Cencora's new segmentation. EBIT estimates remained essentially unchanged, while fiscal 2027 and 2028 earnings-per-share estimates were reduced by 1.4 percent.
Broker revisions meet transaction risk
The revised view adds to a week of broker attention around Cencora's growth profile. Wells Fargo said the valuation gap to a peer could narrow if the company continues to deliver strong and comparable results.
The transaction backdrop remains important. On November 13, the Federal Trade Commission sued to block Covetrus's planned acquisition of MWI Veterinary Supply from Cencora. The agency alleges that the combination would reduce competition in veterinary distribution and lead to higher costs for clinics and pet owners.
Cencora stock traded at 309.15 euros on Lang & Schwarz at 10:57 CET on Saturday, November 21.
Cencora Inc.
- ISIN: US03073E1055
- Ticker: COR
- Primary exchange: New York Stock Exchange
- Lang & Schwarz quote: 309.15 euros at 10:57 CET on November 21, 2026
U.S. market conditions remain the relevant backdrop for Cencora investors; see Current market reports.
